Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years

INTRODUCTION: The effects of tafamidis on mortality in Val30Met and non-Val30Met patients with transthyretin amyloidosis with polyneuropathy (ATTR-PN) were evaluated. METHODS: The analyses were based on cumulative data from the Val30Met patients in the 18-month double-blind registration study and it...

Descripción completa

Detalles Bibliográficos
Autores principales: Merlini, Giampaolo, Coelho, Teresa, Waddington Cruz, Márcia, Li, Huihua, Stewart, Michelle, Ebede, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229124/
https://www.ncbi.nlm.nih.gov/pubmed/32107748
http://dx.doi.org/10.1007/s40120-020-00180-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229124/
https://www.ncbi.nlm.nih.gov/pubmed/32107748
http://dx.doi.org/10.1007/s40120-020-00180-w

Ejemplares similares